P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution
- 20 August 2007
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 35 (11), 2076-2085
- https://doi.org/10.1124/dmd.107.017723
Abstract
P-glycoprotein (P-gp)-mediated efflux at the blood-brain barrier has been implicated in limiting the brain distribution of many anti-HIV1 drugs, primarily protease inhibitors, resulting in suboptimal concentrations in this important sanctuary site. The objective of this study was to characterize the interaction of abacavir with P-gp and determine whether P-gp is an important mechanism in limiting abacavir delivery to the central nervous system (CNS). In vitro and in vivo techniques were employed to characterize this interaction. Abacavir stimulated P-gp ATPase activity at high concentrations. The cellular accumulation of abacavir was significantly decreased by ∼70% in Madin-Darby canine kidney II (MDCKII)-MDR1 monolayers compared with wild-type cells and was completely restored by the P-gp inhibitors ((R)-4-((1aR,6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-α-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride) (LY335979) and N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide (GF120918). Directional flux experiments indicated that abacavir had greater permeability in the basolateral-to-apical direction (1.58E-05 cm/s) than in the apical-to-basolateral direction (3.44E-06 cm/s) in MDR1-transfected monolayers. The directionality in net flux was abolished by both LY335979 and GF120918. In vivo brain distribution studies showed that the AUCplasma in mdr1a(-/-) CF-1 mutant mice was ∼2-fold greater than the AUCplasma in the wild type, whereas the AUCbrain in the mutant was 20-fold higher than that in the wild type. Therefore, the CNS drug targeting index, defined as the ratio of AUC brain-to-plasma for mutant over wild type, was greater than 10. These data are the first in vitro and in vivo evidence that a nucleoside reverse transcriptase inhibitor is a P-gp substrate. The remarkable increase in abacavir brain distribution in P-gp-deficient mutant mice over wild-type mice suggests that P-gp may play a significant role in restricting the abacavir distribution to the CNS.This publication has 31 references indexed in Scilit:
- Dementia and Neurocognitive Disorders Due to HIV-1 InfectionSeminars in Neurology, 2007
- Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal FluidAntimicrobial Agents and Chemotherapy, 2005
- Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain BarrierCancer Research, 2004
- Importance of P‐glycoprotein for drug disposition in humansEuropean Journal of Clinical Investigation, 2003
- Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.Journal of Antimicrobial Chemotherapy, 2003
- Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated EffluxThe Journal of pharmacology and experimental therapeutics, 2002
- Role reversal for anticancer agents.Cancer Biology & Therapy, 2002
- 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activityAntimicrobial Agents and Chemotherapy, 1997
- Drug Equilibration Across the Blood—Brain Barrier-Pharmacokinetic Considerations Based on the Microdialysis MethodPharmaceutical Research, 1997
- Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.Proceedings of the National Academy of Sciences of the United States of America, 1989